In preclinical models, blockade of this pathway synergistically enhances the efficacy of immune checkpoint blockade (e.g., anti-PD-1/PD-L1), as evidenced by increased infiltration of CD8+ cytotoxic T cells, and a concurrent reduction in Tregs and tumor-associated neutrophils (25). Here, PDCD1 is linked to neoplasm.